SCHEMBL5262473

SCHEMBL5262473

O=C(Cc1ccc(-c2ccccc2)cc1)Nc1ccc2c(C=C(C(=O)O)c3ccccc3)c[nH]c2n1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
CDK2 P24941 3/20 0.43
CCNA2 P20248 2/20 0.43
CCNA1 P78396 2/20 0.43
WNT3A P56704 7/20 0.43
CCNE1 P24864 1/20 0.42
CDK9 P50750 1/20 0.42
CDK5 Q00535 1/20 0.42
CDK5R1 Q15078 1/20 0.42
RAB9A P51151 2/20 0.41
RIOK2 Q9BVS4 1/20 0.39
NPC1 O15118 1/20 0.38
NPY5R Q15761 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5262468 1.00 KMT2A (0.47) KMT2AMEN1SLC6A2SLC6A3CDK2
SCHEMBL5261663 0.94 DEGS1 (0.41) KMT2AMEN1CDK2CCNA2CCNA1
SCHEMBL5261657 0.94 DEGS1 (0.41) KMT2AMEN1CDK2CCNA2CCNA1
SCHEMBL5259071 0.92 KMT2A (0.46) KMT2AMEN1SLC6A2SLC6A3CDK2
SCHEMBL5259070 0.92 KMT2A (0.46) KMT2AMEN1SLC6A2SLC6A3CDK2
SCHEMBL5259914 0.86 ADORA2A (0.40) KMT2AMEN1CDK2CCNA2CCNA1
SCHEMBL5259908 0.86 ADORA2A (0.40) KMT2AMEN1CDK2CCNA2CCNA1
SCHEMBL5315071 0.86 ADORA2A (0.40) KMT2AMEN1CDK2CCNA2CCNA1
SCHEMBL5257304 0.86 GRM5 (0.46) KMT2AMEN1RAB9ANPC1
SCHEMBL5257301 0.86 GRM5 (0.46) KMT2AMEN1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP claimed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US claimed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US claimed
EP-1309590-B1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PFIZER ITALIA SRL (IT) 2007-09-19 EP disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 KMT2A 1011/4885MEN1 3262/4885SLC6A2 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.